Analysts expect earnings growth to be in the range of 30-40 per cent for drug firms owing to both domestic recovery as well as strong export opportunities
from Latest News https://ift.tt/2XuGIak
Sunday, 10 January 2021
Bright outlook: Sun Pharma to Cipla, drug firms set for Q3 health boost
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment